Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy

Table 3 Possible shRNA nanocarriers for the treatment of malignancies

Nanoformulation	Tested cancer cell lines	Results of the study	Reference
Hydroxyapatite nanoparticles-delivered plasmid-based SATB1 shRNA	Human glioma U251 cells	Significant inhibition of growth, invasion and angiogenesis, down-regulation of SATB1, cyclin D1, MMP-2 and VEGF, increased Bax and caspase-9 activity	[92]
CD44-targeted shRNA delivered by PLGA-based NPs	Human ovarian SKOV-3 cells	Inhibition of angiogenesis, proliferation of cells and the induction of apoptosis	[45]
PEI-coated gold NPs with chitosan-aconitic anhydride and shRNA	Human hepatocellular carcinoma	Enhancement of sensitivity of cancer cells to doxorubicin, induction of tumor growth, decrease of ABCG2 expression	[91]
PEG-PEI co-polymer/shRNA	Prostate cancer	Effective inhibition of EZH2 expression	[94]
jetPEI-based NPs with CXCR4 shRNA	Melanoma	Decreased expression of CXCR4 mRNA, inhibition of pulmonary metastasis of melanoma cells	[95]

SATB1 special AT-rich sequence-binding protein-1, PLGA poly D, L-Lactide-co-glycolide acid, PEI polyethyleneimine, PEG polyethylene glycol, TREM-1 triggering receptor expressed on myeloid cells-1, EZH2 the enhancer of zeste homolog 2, CXCR4 CXC motif chemokine receptor 4

ISSN: 1477-3155